SCHEMBL7083563

SCHEMBL7083563

CC(=O)NCC1CN(c2ccccc2N2CCOCC2F)C(=O)O1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.55
MAOB P27338 4/20 0.55
PTGS1 P23219 2/20 0.55
SDHA P31040 2/20 0.55
LMNA P02545 1/20 0.55
CALML3 P27482 1/20 0.55
F10 P00742 5/20 0.42
MTNR1A P48039 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28594531 1.00 MAOA (0.55) MAOAMAOBPTGS1SDHALMNA
SCHEMBL7537310 1.00 MAOA (0.55) MAOAMAOBPTGS1SDHALMNA
SCHEMBL28594529 0.86 MAOA (0.62) MAOAMAOBPTGS1SDHALMNA
SCHEMBL7537313 0.86 MAOA (0.62) MAOAMAOBPTGS1SDHALMNA
SCHEMBL483916 0.85 MAOA (0.61) MAOAMAOBPTGS1SDHALMNA
SCHEMBL27707418 0.85 MAOA (0.61) MAOAMAOBPTGS1SDHALMNA
SCHEMBL27875818 0.85 MAOA (0.61) MAOAMAOBPTGS1SDHALMNA
SCHEMBL15141607 0.84 MAOA (0.43) MAOAMAOBPTGS1SDHALMNA
SCHEMBL28998570 0.84 MAOB (0.68) MAOAMAOBPTGS1SDHALMNA
SCHEMBL27801851 0.84 MAOB (0.68) MAOAMAOBPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102174027-A New crystal form of linezolid and preparation method and application thereof Chengdu zihao pharmaceutical co ltd 2011-09-07 CN claimed
US-20030065219-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY 2003-04-03 US claimed
CN-109444294-B High performance liquid chromatography method for separating linezolid and chiral isomer thereof SUZHOU LAIAO BIOTECHNOLOGY Co.,Ltd. (CN) 2021-06-22 CN disclosed
CN-103025730-A Method for preparing linezolid UNIV INDIANA RES & TECH CORP 2013-04-03 CN disclosed
CN-102675239-A Method for preparing linezolid crystal form I KAIYUAN HENGTAI CHEMICAL CO LTD 2012-09-19 CN disclosed
CN-102174027-A New crystal form of linezolid and preparation method and application thereof Chengdu zihao pharmaceutical co ltd 2011-09-07 CN disclosed
US-6562844-B2 Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent PHARMACIA & UPJOHN COMPANY 2003-05-13 US disclosed
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation GORDEEV MIKHAIL F (US) 2002-12-05 US disclosed
CN-1288462-A Oxazolidinone combinatorial libraries, compositions and method of prepn. UPJOHN CO (US) 2001-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065219-A1 PROCESS TO PRODUCE OXAZOLIDINONES ADH1A, ADH5, ADH1C MAOA 156/4885MAOB 189/4885PTGS1 2552/4885
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PAICS, CDK4, OXA1L MAOA 1267/4885MAOB 1298/4885PTGS1 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.